© Stockopedia 2020-02-03,12:04:43 Market Cap £14.3m Quality 37 Novacyt SA Enterprise Value £20.9m Value 61 Revenue £11.7m Momentum 84 NCYT 45.99p 8.0 21.0% Market Cap Rank 1452nd / 1833 StockRank™ 68 Highly Speculative, Micro Cap, Turnaround Zoom 1m 3m 6m YTD 1y 2y 3y 5y All vs. vs. Momentum Growth & Value industry market Relative Strength (%) 12m Forecast Rolling 40 1m +201.3% PE Ratio (f) 3.23 3m +456.2% PEG Ratio (f) 0.057 EPS Growth (f) 133.3 % 1yr +1.9% 20 Dividend Yield (f) n/a % Volume Change (%) Valuation (ttm) 10d v 3m +719.8% Price to Book Value 0.92 0 Price vs... (%) Price to Tang. Book n/a Mar '19 May '19 Jul '19 Sep '19 Nov '19 Jan '20 52w High -27.6% Price to Free Cashflow n/a 50d MA +179.5% Price to Sales 1.22 2018 2019 2020 200d MA +258.6% EV to EBITDA 22.7 vs. vs. Margin of Safety (beta) ◀ Screens Passed ▶ Quality industry market Broker Target 88% Return on Capital -2.36 % NCYT doesn't qualify for any screens. Return on Equity -7.11 % Relative to Sector 319% Find out why: View Checklists Operating Margin -3.88 % Financial Summary Balance Sheet · Income Statement · Cashflow Health Trend Piotroski F-Score 6 Year End 31st Dec 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg Revenue €m 1.15 4.53 8.89 11.1 12.7 13.7 13.9 21.0 28.0 +64.1% Operating Profit €m -1.00 -3.69 -13.2 -4.46 -2.12 -1.39 -0.54 Bankruptcy Risk Altman Z1-Score -0.86 Net Profit €m -1.00 -3.91 -13.9 -5.71 -5.44 -4.74 -4.89 2.20 3.00 EPS Reported € -0.34 -0.88 -2.05 -0.47 -0.15 -0.056 -0.037 EPS Normalised € -0.36 -0.86 -1.10 -0.45 -0.14 -0.049 -0.035 0.060 0.14 EPS Growth % +133.3 Earnings Manipulation Risk PE Ratio x n/a n/a 7.53 3.23 PEG x n/a n/a 0.057 n/a Magic Formula Score 1864 34% D+ Profitability Operating Margin % -86.2 -81.6 -148.3 -40.3 -16.6 -10.1 -3.88 -63.9% D+ ROA % -26.3 -63.6 -24.0 -10.8 -4.43 ROCE % -42.8 -17.2 -103.2 -20.6 -8.1 -6.1 -2.36 -33.0% Other Ratios ROE % -34.7 -90.3 -40.4 -16.4 -9.4 -7.11 -38.2% Leverage (ttm) total -intang +pension Cashflow Gross Gearing % 45.9 45.9 Op. Cashflow ps € -0.28 -0.47 -0.79 -0.21 -0.20 -0.033 0.002 Net Gearing % 42.6 42.6 Capex ps € 0.20 0.12 0.12 0.045 0.042 0.018 0.022 -38.0% Cash / Assets % 1.78 1.78 Free Cashflow ps € -0.48 -0.60 -0.91 -0.26 -0.24 -0.051 -0.020 Liquidity (ttm) Efficiency (ttm) Dividends Curr. Ratio 0.65 Asset Turnover 0.42 Dividend ps € Quick Ratio 0.44 Rec's Turnover 4.00 Dividend Growth % Interest Cov. -0.71 Stock Turnover 2.21 Dividend Yield % Dividend Cover x vs. vs. Recent History industry market Balance Sheet Cash etc €m 1.00 2.34 1.69 2.87 4.36 1.14 0.61 +2.7% Latest interim period (ended 30th Jun '19) vs. prior year Working Capital €m 1.10 0.67 1.27 -1.46 3.13 -2.09 -3.95 Sales Growth 12.4 % Net Fixed Assets €m 0.17 0.61 0.94 1.28 1.81 3.72 6.24 +85.4% EPS Growth n/a % Net Debt €m -0.79 -1.32 1.68 4.34 -0.46 4.23 7.88 3yr Compound Annual Growth Rate Book Value €m 2.25 20.3 10.5 17.8 24.9 20.1 18.5 +55.0% Sales Growth 15.6 % Average Shares m 2.93 4.44 6.79 12.1 23.1 37.7 30.4 +66.7% EPS Growth n/a % Book Value ps € 0.76 3.23 1.46 1.02 0.66 0.53 0.49 -6.8% DPS Growth n/a % Graphical History Current Fiscal Year 2019 Revenue Net Profit Normalised EPS PE Ratio Range Dividend Yield Range 30m 5m 0.5 20m -5m 0 0 10m -0.5 -10m -1 20 3 20 4 20 5 20 6 20 7 20 8 20 9 20 20 3 20 4 20 5 20 6 20 7 20 8 20 9 20 20 3 20 4 20 5 20 6 20 7 18 20 9 20 14 15 16 17 18 19 14 15 16 17 18 19 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 © Stockopedia 2020-02-03,12:04:43 Broker Forecasts 31st Dec 2019 31st Dec 2020 Broker Consensus Trend 1 Broker Price Target: €0.85 Net Profit EPS DPS Net Profit EPS DPS (+88.01% above Price) 1 Est. Long Term Growth Rate: n/a (€) (€) (€) (€) (€) (€) 2019 EPS Consensus Estimate 2.20m 0.060 - 3.00m 0.14 - 1m Change - - - - - - 3m Change - - - - - - Feb Apr Jun Aug Oct Dec Feb 2019 2019 2019 2019 2019 2019 2020 Profile Summary Novacyt SA is a France-based company that develops and markets solutions dedicated to the eld of liquid-based cytology and molecular biology. The Company develops a secure automated cytology named NovaPrep Processor System. Novacyt SA o ers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The Company creates bottles speci cally dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of over 10 distributors. Directors: Anthony Dyer (CFO) , Paul Eros (EXB) , Wendy Karban (CHO) , Graham Mullis (CEO) 54, Mandy Cowling (DIR) , Steve Gibson (EXB) , Jean-Pierre Crinelli (NED) 68, Ian Wilde (EXB) , James Wakefield (NEC) , Andrew Heath (NID) 70, Ruth Powell (EXB) , Phillip Sefton (EXB) , Juliet Thompson (NID) 52, Edwin Snape (NID) 79, No. of Employees: 119 No. of Shareholders: n/a Last Annual December 31st, 2018 Sector Healthcare Last Interim June 30th, 2019 Industry Biotechnology & Medical Research Address 13 avenue Morane Saulnier, VELIZY Index Incorporated July 3, 2006 VILLACOUBLAY, 78140, France Exchange London Stock Exchange (Dual Listing) Public Since October 12, 2012 Web https://novacyt.com/ Eligible for an ISA? a SIPP? Phone +33 1 39465104 Shares in Issue 37,664,342 Contact Graham Mullis (Chief Executive Officer, Free Float 35.8m (95.2%) Executive Director, Member of the Executive Team) Auditors Deloitte & Associes NCYT Share Price Quote NCYT Share Price Performance 1 year NCYT Share Price Day's Change Volume Bid - Ask Low - High Spread GBp 5,857,445 44.0 - 46.0 50.0 - 50.0 435bps 8.0 21.0% Avg Vol (3m) Open - Close 12m Range Beta 3 month 45.99p 181,859 43.5 - 38.0 0.0 - 0.0 0.00 0% 200% 400% 600% Traded 11:46am · Minimum 15 min delayed · NMS: 5.00k Latest NCYT News Announcements (delayed) More » s Industry Peer Group t Summit Therapeutic… Fri 7:11am Healthcare company Novacyt launches new coronavirus test Compare vs NCYT 2nd Jan '18 Novacyt S.A. - Liquidity Agreement Update and Total Voting Rights MaxCyte Inc Compare vs NCYT 2nd Jan '18 RCS - Novacyt S.A. - PLACED IN TECHNOLOGY FAST 500 EMEA AWARDS Yourgene Health 1st Dec '17 Novacyt S.A. - Liquidity Agreement Update and Total Voting Rights Compare vs NCYT 7th Nov '17 Novacyt S.A. Legal & General Grp - Notification of major holdings Faron Pharmaceutic… Compare vs NCYT Oxford Biodynamics Compare vs NCYT Upcoming NCYT Events Circassia Pharmace… Compare vs NCYT Recent ¯ Shield Therapeutic… Compare vs NCYT Bioventix Compare vs NCYT Healthcare Biotechnology & Medical Research Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as speci cally authorised; and (c) are not warranted to be complete, accurate or timely. © Stockopedia 2020-02-03,12:04:43 You should independently research and verify any information that you nd in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may su er arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2020.
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-